WO2002017959A3 - Immunosuppression using piceatannol and a calcineurin inhibitor - Google Patents

Immunosuppression using piceatannol and a calcineurin inhibitor Download PDF

Info

Publication number
WO2002017959A3
WO2002017959A3 PCT/US2001/023564 US0123564W WO0217959A3 WO 2002017959 A3 WO2002017959 A3 WO 2002017959A3 US 0123564 W US0123564 W US 0123564W WO 0217959 A3 WO0217959 A3 WO 0217959A3
Authority
WO
WIPO (PCT)
Prior art keywords
piceatannol
immunosuppression
calcineurin inhibitor
transplant
cyclosporin
Prior art date
Application number
PCT/US2001/023564
Other languages
French (fr)
Other versions
WO2002017959A2 (en
Inventor
Majed M Hamawy
Stuart J Knechtle
Original Assignee
Wisconsin Alumni Res Found
Majed M Hamawy
Stuart J Knechtle
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wisconsin Alumni Res Found, Majed M Hamawy, Stuart J Knechtle filed Critical Wisconsin Alumni Res Found
Priority to US10/363,494 priority Critical patent/US20040033941A1/en
Priority to AU2001277199A priority patent/AU2001277199A1/en
Publication of WO2002017959A2 publication Critical patent/WO2002017959A2/en
Publication of WO2002017959A3 publication Critical patent/WO2002017959A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection

Abstract

Disclosed herein are methods and drugs for suppressing acute/chronic rejection responses of a transplant recipient. Piceatannol and calcineurin inhibitors such as cyclosporin A and FK506 are administered in a combined protocol shortly before, and/or after, the transplant. They can be injected in an organic solvent, or other carrier.
PCT/US2001/023564 2000-08-28 2001-07-25 Immunosuppression using piceatannol and a calcineurin inhibitor WO2002017959A2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US10/363,494 US20040033941A1 (en) 2001-07-25 2001-07-25 Immunosuppression using piceatannol and a calcineurin inhibitor
AU2001277199A AU2001277199A1 (en) 2000-08-28 2001-07-25 Immunosuppression using piceatannol and a calcineurin inhibitor

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US22855100P 2000-08-28 2000-08-28
US60/228,551 2000-08-28
US27950201P 2001-03-28 2001-03-28
US60/279,502 2001-03-28

Publications (2)

Publication Number Publication Date
WO2002017959A2 WO2002017959A2 (en) 2002-03-07
WO2002017959A3 true WO2002017959A3 (en) 2003-03-13

Family

ID=26922465

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2001/023564 WO2002017959A2 (en) 2000-08-28 2001-07-25 Immunosuppression using piceatannol and a calcineurin inhibitor

Country Status (2)

Country Link
AU (1) AU2001277199A1 (en)
WO (1) WO2002017959A2 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI20012565A (en) * 2001-12-21 2003-06-22 Eero Mervaala Products for use in immunisuppressive therapy
JP2007530417A (en) * 2003-07-01 2007-11-01 プレジデント・アンド・フェロウズ・オブ・ハーバード・カレッジ Composition for manipulating the longevity and stress response of cells and organisms
JP2007527418A (en) 2003-12-29 2007-09-27 プレジデント・アンド・フェロウズ・オブ・ハーバード・カレッジ Composition for treating or preventing obesity and insulin resistance disorders
US8017634B2 (en) 2003-12-29 2011-09-13 President And Fellows Of Harvard College Compositions for treating obesity and insulin resistance disorders
WO2006138418A2 (en) 2005-06-14 2006-12-28 President And Fellows Of Harvard College Improvement of cognitive performance with sirtuin activators
WO2007084857A2 (en) * 2006-01-13 2007-07-26 President And Fellows Of Harvard College Methods and compositions for treating cell proliferative disorders

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
ISHIDO, NOBUHIRO ET AL: "The selective Syk/ZAP tyrosine kinase blocker piceatannol synergizes with cyclosporin A in prolonging cardiac allograft survival in rats", SURGICAL FORUM (2000), 51, 345-346, XP008010090 *
KNECHTLE S J: "Rejection of the liver transplant.", SEMINARS IN GASTROINTESTINAL DISEASE, (1998 JUL) 9 (3) 126-35. REF: 65, XP008010089 *
OLIVER JANET M ET AL: "Inhibition of mast cell Fc-epsilon-R1-mediated signaling and effector function by the Syk-selective inhibitor, piceatannol.", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 269, no. 47, 1994, pages 29697 - 29703, XP002221044, ISSN: 0021-9258 *

Also Published As

Publication number Publication date
AU2001277199A1 (en) 2002-03-13
WO2002017959A2 (en) 2002-03-07

Similar Documents

Publication Publication Date Title
WO2007027445A3 (en) Method and apparatus for dual mode mobile station call delivery
WO2001037785A3 (en) Novel methods and compositions involving opioids and antagonists thereof
WO2002008217A3 (en) COUMARIN DERIVATIVES USEFUL AS TNFα INHIBITORS
PL1727551T3 (en) Pharmaceutical composition comprising a benzodiazepine derivative and a inhibitor of the rsv fusion protein
HK1098372A1 (en) Pharmaceutical composition comprising a benzodiazepine derivative and an inhibitor of the rsv fusion protein
WO2001078680A3 (en) Pharmaceutical compositions comprising fluvastatin
AP2421A (en) Quinoline derivatives and their use as mycobacterial inhibitors.
WO2007098352A3 (en) Substituted pyridineamide compounds useful as soluble epoxide hydrolase inhibitors
WO2005089317A3 (en) Immune response modifier formulations and methods
WO2007067836A3 (en) Substituted pyrazole compounds useful as soluble epoxide hydrolase inhibitors
AR033342A1 (en) A TOPIC OR INTRANASAL OTHICAL COMPOSITION TO TREAT OTICO PAIN AND THE TOPICAL USE OF KAPA OPIOID AGONISTS TO TREAT OTICO PAIN
WO2000040203A3 (en) Polymeric delivery agents and delivery agent compounds
WO2003094790A3 (en) Catheter system with procedural catheter and embolic proctection system
EP1913945A3 (en) Composition based on a thiazolidinedione and metformin and its use
WO2006096173A8 (en) Pharmaceutical compositions and methods for peptide treatment
WO2008084698A1 (en) Tacrolimus sustained release pharmaceutical composition
RS106704A (en) Stabilised pharmaceutical compositions on the basis of polyoxyethylated castor oil and method for manufacturing the same
WO2002017959A3 (en) Immunosuppression using piceatannol and a calcineurin inhibitor
WO2006135811A3 (en) Method of use of antagonists of zonulin to prevent the loss of or to regenerate pancreatic cells
WO2001078653A3 (en) Graft rejection inhibition with ccr2 inhibitors
AU2003229835A1 (en) Compounds, compositions and method for transporting cyclosporin molecules through the blood brain barrier
WO2003082881A3 (en) Pyridoxal-5-phosphate derivatives as hiv integrase inhibitors
EP1105102B8 (en) Pharmaceutical composition for injection based on a pharmaceutically acceptable clopidogrel or ticlopidin salt
WO2002015892A3 (en) Combination comprising an insulin secretion enhancer and an active ingredient selected from hmg-co-a reductase inhibitors and ace inhibitors
AU3048501A (en) An improved pharmaceutical composition for treating male erectile dysfunction

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 10363494

Country of ref document: US

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP